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 Purpose: To assess the prognostic implications of mediastinal posi-
tron emission tomographic (PET) fi ndings in patients un-
dergoing curative resection of non–small cell lung cancer 
(NSCLC) who have histologically negative mediastinal 
lymph nodes (LNs), with the hypothesis that positive fi nd-
ings at PET are prognostic even in patients with negative 
histologic fi ndings in the LNs.
 Materials and 
Methods: 
Records of patients with a preoperative PET undergoing 
curative surgery, without adjuvant radiation, for pathologic 
T1–3N0–1 NSCLC at the University of North Carolina be-
tween 2000 and 2006 were reviewed as an institutional 
review board–approved HIPAA-compliant retrospective 
study. Ninety patients were evaluable (all histologically 
negative in mediastinum; 44 with both mediastinoscopy and 
surgery); 13 patients had positive mediastinal PET fi ndings, 
and 77 had negative mediastinal PET fi ndings. Local-regional 
and distant failure rates in patients with and those with-
out mediastinal abnormalities at preoperative PET were 
compared by using logistic regression and log-rank tests.
 Results: Median follow-up was 54.3 months (range, 1–99 months). 
There were higher rates of local-regional ( P = .001) and 
distant ( P  , .001) failure as well as death ( P = .001) in pa-
tients with postive PET fi ndings than in patients with nega-
tive fi ndings. In multivariable analysis (adjusting for other 
prognostic factors), positive PET fi ndings in the mediasti-
num remained prognostic for distant failure ( P  , .001, 
hazard ratio = 6.9) and were marginally prognostic for 
local-regional failure ( P = .093, hazard ratio = 1.9).
 Conclusion: Positive fi ndings at preoperative PET in the mediastinum 
appear to have prognostic implications despite the me-
diastinal LNs being histologically negative. The high rate 
of local-regional and distant failure suggests that postop-
erative radiation therapy and/or chemotherapy may be 
particularly helpful in patients with positive mediastinal 
fi ndings at preoperative PET.
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 PET Technique 
 PET/CT scans with fl uorine 18 fl uoro-
deoxyglucose (FDG) were performed by 
using a dedicated PET scanner (Single-
Slice Biograph or Biograph 40; Sie-
mens, Knoxville, Tenn). Patients fasted 
for at least 6 hours before FDG injec-
tion. PET acquisition started approxi-
mately 60 minutes after the intrave-
nous administration of approximately 
444 MBq of FDG. PET/CT images were 
typically obtained from the base of the 
brain through the proximal thighs and 
were reconstructed in three planes. An 
unenhanced CT scan was obtained for 
attenuation correction and anatomic 
correlation. 
 Mediastinal nodal stations were de-
fi ned on the basis of the International 
Association of the Study of Lung Can-
cer LN map ( 1 ). The PET fi ndings in 
the mediastinum were categorized by 
using two methods. 
 Visual evaluation was the fi rst method. 
Two of a group of nuclear medicine 
specialists (residents with 1–4 years ex-
perience, including M.R.J. with 4 years 
experience, and faculty with 10–40 years 
experience, including A.H.K. with 10 years 
experience) visually evaluated all PET/CT 
to assess the logic of this approach. It 
is certainly possible that these discor-
dant fi ndings between PET and histologic 
analysis represent, in part, inaccuracies 
in the histologic assessment of the me-
diastinal LNs (eg, surgical sampling or 
pathologic techniques). 
 We herein assess the prognostic im-
plications of mediastinal PET fi ndings in 
patients undergoing curative resection 
of NSCLC who have a histologically 
negative mediastinum with the hypoth-
esis that positive fi ndings at PET are 
prognostic even in patients with nega-
tive histologic fi ndings in the LNs. 
 Materials and Methods 
 The medical records of all patients who 
underwent surgery for lung cancer at the 
University of North Carolina between 
2000 and 2006 were reviewed for our 
institutional review board–approved 
Health Insurance Portability and Ac-
countability Act–compliant retrospec-
tive study . Ninety patients who met the 
following criteria comprised our study 
population: pathologic stages T1–3N0–1 
NSCLC, undergoing lobectomy or pneu-
monectomy (wedge resection was ex-
cluded), the mediastinum was patho-
logically assessed, all surgical margins 
were negative, no neoadjuvant or adju-
vant radiation therapy, no neoadjuvant 
chemotherapy, preoperative evaluation 
(typically including bronchoscopy, ab-
dominal CT, and usually brain magnetic 
resonance [MR] imaging or CT, if ap-
plicable) resulted in M0 staging, had 
preoperative PET of the chest or whole 
body, and no metachronous lung can-
cers treated during the 2 years prior to 
the current resection. The study schema 
is shown in  Figure 1 . Clinical data were 
extracted retrospectively from the elec-
tronic medical records (eg, clinical, 
radiologic, and/or pathologic notes). 
 Accurate staging is a cornerstone of cancer care, guiding both treat-ment and prognosis. For non–
small cell lung cancer (NSCLC), the 
most commonly used staging system is 
adopted from TNM classifi cation of the 
American Joint Committee on Cancer 
revised by the International Associa-
tion of the Study of Lung Cancer ( 1 ). In 
this framework, patients with disease 
in the mediastinal lymph nodes (LNs) 
at histologic analysis are considered to 
be stage III and are usually treated with 
defi nitive chemotherapy and radiation 
therapy, while those without evidence of 
disease in mediastinal LNs at histologic 
analysis are considered to be stage I or 
II and are treated with surgery ( 2 ). 
 The routine staging of the mediasti-
num in patients with NSCLC includes 
computed tomography (CT) of the chest, 
mediastinoscopy, and, more recently, 
positron emission tomography (PET). 
PET can be used to identify tissues with 
a high metabolic rate, such as cancer. 
Many studies have compared the sensi-
tivity, specifi city, and positive and nega-
tive predictive values of CT versus PET 
versus both, with the histologic analysis 
essentially always used as the reference 
standard ( 3,4 ). The positive predictive 
value of PET in the mediastinum is re-
ported to be 80%–90% ( 5 ). The remain-
ing 10%–20% is thought to be false-
positive PET fi ndings, and treatment 
decisions are based on the histologic 
fi ndings. Our analysis was undertaken 
 Implication for Patient Care 
 The high rate of local-regional and  n
distant failure suggests that post-
operative radiation therapy and/or 
chemotherapy may be helpful in 
patients with a positive mediasti-
nal fi ndings at preoperative PET. 
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lymph node fi ndings at preopera-
tive PET have higher 5-year failure 
rates than those with negative 
fi ndings (local-regional failure: 
68.3% vs 18.6%,  P = .001; distant 
failure: 66.4% vs 9.8%,  P  , .001) 
despite negative histologic fi ndings. 
 These patients also have a worse  n
prognosis (5-year overall mortal-
ity: 76.9% vs 36.5%,  P = .001); 
therefore, preoperative evalua-
tion of the mediastinum with 
PET may complement surgical 
and histological fi ndings. 
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regressions of crude incidence rates of 
local-regional and distant failures were 
performed to investigate their associa-
tion with PET results in the mediasti-
num. The Kaplan-Meier method and 
log-rank tests were used for the estima-
tion and comparison of actuarial local-
regional and distant failure rates and 
overall mortality rates between the two 
subgroups. Univariate and multivariate 
Cox proportional hazards models were 
used to assess the potential relationship 
between prognostic outcomes and po-
tentially confounding covariates, includ-
ing sex, lymphovascular space invasion, 
tumor histologic grade (World Health 
Organization classifi cation), pleural in-
volvement, primary tumor size, number 
of sampled ipsilateral mediastinal LNs 
(N2), histologic fi ndings (ie, squamous 
vs nonsquamous carcinoma), left- versus 
right-sided tumor, type of surgery (lobec-
tomy, bilobectomy, or pneumonectomy), 
and postoperative chemotherapy use. 
For SUV analysis, binary logistic regres-
sion of crude incidence rates was per-
formed to investigate their association 
with the subgroups based on 
medLNmax
SUV . 
The overall prognostic value of the 
medLNmax
SUV  was assessed by using the 
area under the receiver operating char-
acteristic curve by using the trapezoi-
dal rule for local-regional and distant 
failures. Analysis was carried out by 
using PASW Statistics software (version 
18.0; SPSS, Chicago, Ill). A  P value of 
less than .05 was considered to indicate 
a signifi cant difference without correc-
tion for multiple hypothesis testing, since 
this is a preliminary or exploratory study 
and may be considered to be hypothesis 
generating. 
 Results 
 Patient Characteristics 
 Clinical characteristics of the 90 pa-
tients included in this analysis are shown 
in  Table 1 . Median follow-up in all pa-
tients was 54.3 months (range, 1–99 
months), and that in survivors was 
71.7 months (range, 47–99 months). 
Mediastinoscopy was performed in 44 
patients. The median number of total 
mediastinal nodal stations sampled for 
surgery (VATS). All patients had the 
mediastinal LNs staged at mediasti-
noscopy and/or mediastinal sampling 
during lobectomy or pneumonectomy. 
Nodal sampling was performed at the 
surgeon’s discretion, but mediastinal 
dissection was not performed routinely. 
In all cases, all mediastinal nodal tis-
sue was negative for malignancy on 
permanent sections, with or without 
frozen sections, if taken during sur-
gery. The TNM stage was assigned ac-
cording to the seventh edition of the 
American Joint Committee on Cancer 
manual ( 1 ). 
 End Points and Statistical Analysis 
 A local-regional failure was defi ned 
by using either CT progression or FDG 
PET avidity as a new or enlarging mass 
at the site of surgical resection (eg, ip-
silateral lung, surgical stump, hilum, 
chest wall, mediastinum) that, in the 
patient’s subsequent clinical follow-up, 
was consistent with disease progres-
sion. An enlarged LN or increased tis-
sue thickening at the resection margin 
at CT, or an equivocal fi nding at PET, 
that failed to progress was not consid-
ered as a failure. Where possible and 
clinically relevant, some patients under-
went biopsy of a suspected recurrence. 
A distant failure was a failure beyond 
either the surgical bed or regional LNs. 
Time to failure was defi ned as the inter-
val from the date of surgery until fail-
ure. Patients not experiencing a failure 
were censored at the date of their 
last follow-up or at death. Follow-up 
survival status was obtained from the 
University of North Carolina registry 
and the Social Security death index. 
Overall survival time was defi ned as the 
interval from the date of surgery until 
the date of death due to any cause. 
 The goal of our study was to com-
pare the outcomes of patients with pos-
itive mediastinum PET fi ndings versus 
those with negative fi ndings. The Fisher 
exact and Mann–Whitney tests were 
used to examine the distribution of 
categorical and continuous patient char-
acteristic parameters, respectively, in 
the two subgroups (ie, those with posi-
tive PET mediastinal fi ndings and those 
with negative fi ndings). Binary logistic 
images for each patient in concert to 
render a consensus opinion in the clinical 
record. PET/CT fi ndings of the mediasti-
num were recorded from the reports is-
sued at the time of interpretation, with 
mediastinal LNs being broadly reported 
as malignant or not by using mediasti-
nal blood pool activity as a background. 
Both attenuation-corrected and non–
attenuation-corrected images were rou-
tinely reviewed. The fi ndings on a PET 
report refl ected the overall interpreta-
tion from these two sets of PET images; 
appearance on the CT study; and the 
pretest likelihood of disease in certain 
mediastinal nodal stations, including lo-
cation (central vs peripheral) and size 
of the primary tumor, relative location 
of the nodal station to primary site, and 
possible false-positive conditions (eg, in-
fection, benign infl ammatory disease, 
rheumatoid disease). 
 Standardized uptake value (SUV) 
was the second method. SUV was de-
fi ned as the activity per milliliter within 
the region of interest divided by the 
injected dose in megabecquerels per 
gram of body weight, and maximum 
SUV (SUV max ) was defi ned as the activ-
ity measured in the most intense voxel 
within this region of interest. The SUV 
calculation was done retrospectively for 
the purposes of our study. SUV max was 
measured by placing a three-dimensional 
region of interest around each medi-
astinal nodal station by using the stan-
dard software provided by the manufac-
turer (Syngo MI Workplace; Siemens, 
Malvern, Pa). All measured mediastinal 
lesions had to be visible, and the re-
gions of interest were selected on the 
basis of visibility. The highest SUV max 
of all nodal stations in the mediastinum 
(
medLNmax
SUV ) for each patient was ana-
lyzed. This analysis was performed by 
two experienced physicians (M.R.J. and 
A.H.K., with 4 and 10 years experience, 
respectively) who were blinded to any 
other relevant information, including 
the reports issued at the time of clinical 
reading of the scans. 
 Histologic Staging of the Mediastinum 
 All patients underwent anatomic resec-
tion of all gross tumors with either thora-
cotomy or video-assisted thoracoscopic 
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data (eg, drive loss). Median 
medLNmax
SUV  
was 2.75 (range, 1.67–5.49). The crude 
rate of local-regional failure for the 
patients with a 
medLNmax
SUV  below the me-
dian was seven of 24 versus eight of 24 
for that above the median ( P = .755). 
Comparable rates of distant failure were 
four versus seven, respectively, both out 
of 24 ( P = .303). 
mediastinum remained prognostic for 
distant failure ( P  , .001, hazard ratio = 
6.9) and were marginally prognostic for 
local-regional failure ( P = .093, hazard 
ratio = 1.9). 
 SUV max Analysis 
 SUV max data were available in only 
48 patients owing to loss of archival 
each patient during mediastinal sam-
pling procedures (ie, mediastinoscopy 
and/or surgery) was three (range, 1–7). 
One patient with negative mediastinal 
fi ndings at PET had cardiac arrhyth-
mia several days after surgery and died 
about one month after surgery with no 
sign of cancer progression. 
 Forty-eight patients had SUV max data 
for mediastinal LNs available. In all pa-
tients with positive mediastinal LNs at 
PET, it was the surgeon’s intent to sam-
ple the mediastinal nodal station with 
the highest SUV max during subsequent 
surgical and histologic staging. 
 Analysis of Visual Assessment of PET 
 Thirteen patients had positive PET me-
diastinal fi ndings, and 77 had negative 
fi ndings ( Table 2 ). In the entire group, 
the crude rates of local-regional, distant, 
and all failures were higher in group 
with positive PET fi ndings versus the 
group with negative PET fi ndings. Simi-
lar fi ndings were seen in a subgroup of 68 
patients with pathologically determined 
N0 disease. Actuarial estimates of local-
regional and distant failures, as well as 
overall mortality, are shown in  Figure 2 . 
 Univariate analyses of above-
mentioned covariates are shown in 
 Table 3 . The results of multivariate analy-
ses performed to assess the associa-
tion between positive PET LN fi ndings 
and local-regional and distant failure, 
controlling for these covariates, are 
shown in  Table 3 . PET fi ndings in the 
 Table 1 




( n = 90)
Positive 
( n = 13)
Negative 
( n = 77)  P Value
Sex .23
 Female 37 (41) 3 (23) 34 (44)
 Male 53 (59) 10 (77) 43 (56)
Median age (y) * 66 (38–88) 68 (41–81) 66 (38–88) .69
Tumoral stage .21
 T1 32 (36) 2 (15) 30 (39)
 T2 32 (36) 5 (39) 27 (35)
 T3 26 (29) 6 (46) 20 (26)
Nodal stage .08
 N0 68 (76) 7 (54) 61 (79)
 N1 22 (24) 6 (46) 16 (21)
Histologic fi nding .02
 Squamous cell carcinoma 40 (44) 10 (77) 30 (39)
 Adenocarcinoma † 44 (49) 2 (15) 42 (55)
 Adenosquamous cell carcinoma 2 (2) 0 2 (3)
 Large-cell carcinoma 3 (3) 1 (8) 2 (3)
 Other 1 (1) 0 1 (1)
Histologic grade .09
 1 5 (6) 0 5 (7)
 2 44 (49) 3 (23) 41 (53)
 3 39 (43) 10 (77) 29 (38)
Lymphovascular space invasion 17 (19) 4 (31) 13 (17) .26
Pleural involvement 13 (14) 4 (31) 9 (12) .09
Location .77
 Right 53 (59) 7 (54) 46 (60)
 Left 37 (41) 6 (46) 31 (40)
Bronchoscopy 55 (61) 9 (69) 46 (60) .76
Mediastinoscopy 44 (49) 11 (85) 33 (43) .01
Brain MR imaging and/or CT 20 (22) 2 (15) 18 (23) .72
Type of surgery .18
 Lobectomy 71 (79) 9 (69) 62 (81)
 Bilobectomy 6 (7) 0 6 (8)
 Pneumonectomy 13 (14) 4 (31) 9 (12)
Median no. of sampled N2 stations ‡ 3 (1–7) 4 (2–5) 3 (1–7) .01
Postoperative chemotherapy 12 (13) 2 (15) 10 (13) .68
Note.—Unless otherwise specifi ed, data are numbers of patients, with percentages in parentheses.
* Data in parentheses are ranges.
 † Including bronchioloalveolar carcinoma.
 ‡ Data are numbers of mediastinal LN stations sampled or dissected during mediastinoscopy and/or surgery, with ranges in 
parentheses. Individual stations defi ned in accordance with International Association of the Study of Lung Cancer LN map.
 Figure 1 
  
 Figure 1: Study schema.  NSCLCa = NSCLC. 
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[pulmonary ligament]). The sensitivity 
of mediastinoscopy is reported to vary 
from 81%–89% compared with open 
surgery ( 10–12 ). A recently published 
randomized trial ( 13 ) considered me-
diastinoscopy versus endoscopic ultra-
sonography for mediastinal staging; a 
false-negative rate of 10.3% (six of 58) 
was found in those undergoing medias-
tinoscopy plus endosonography at the 
time of thoracotomy and nodal dissec-
tion conforming to European Society for 
Thoracic Surgery guidelines ( 14 ). Over-
all, mediastinoscopy is believed to have 
an average false-negative rate of 11%, 
with histologic examination after thora-
cotomy as the reference standard ( 15 ). 
 Since ipsilateral nodal involvement 
is more common than contralateral 
nodal disease, open thoracotomy and 
VATS are thought to be more accu-
rate than the mediastinoscopy. With 
of imaging tests are widely acknowl-
edged ( 3,8 ), and sensitivity, specifi city, 
and positive and negative predictive val-
ues are usually used to compare the 
imaging fi ndings with the reference-
standard pathologic assessments. Our 
analysis suggests that PET might pro-
vide complementary prognostic infor-
mation beyond that afforded by patho-
logic fi ndings. It suggests that treatment 
recommendations might perhaps be in-
fl uenced by the pathologic fi ndings and 
the imaging results. 
 The two main approaches to access 
the mediastinum are mediastinoscopy 
and open thoracotomy or VATS ( 9 ). 
Mediastinoscopy has the advantage of 
allowing assessment of bilateral nodal 
stations, but some stations are not well 
accessed with the standard cervical 
approach (eg, levels 5 [subaortic], 6 
[paraaortic], 8 [paraesophageal], and 9 
 Receiver operating characteristic 
curve analyses of 
medLNmax
SUV  for local-
regional and distant failure and overall 
mortality are shown in  Figure 3 . For 
these same three end points, there are 
no differences in the actuarial estimates 
between patients with an 
medLNmax
SUV  
below the median and those with an 
medLNmax
SUV  above the median ( Fig 3 ). 
 Discussion 
 Lung cancer is an aggressive disease 
that typically infi ltrates local-regional 
LNs and also has a high propensity for 
a distant metastatic spread. Following 
resection, the risk for local-regional and 
distant progression is related to the 
pathologic stage ( 6,7 ). 
 Noninvasive diagnostic imaging tests, 
such as CT and PET, are routinely used to 
defi ne the tumor extent. Inadequacies 
 Table 2 
 End Point–related Results in PET-Positive Mediastinum versus PET-Negative Patient Groups 
All Patients Positive PET LN Findings Negative PET LN Findings
Parameter No. of Patients * Percentage No. of Patients * Percentage No. of Patients * Percentage  P Value Odds Ratio
All Nodal Stages
Crude incidence rates
 All failures 28/90 31.1 9/13 69.2 19/77 24.7 .003 7
 Local-regional failure 22/90 24.4 7/13 53.8 15/77 19.5 .012 5
 Distant failure 15/90 16.7 7/13 53.8 8/77 10.4 .001 10
5-year actuarial failure rates
 Local-regional failure … 24.9 … 68.3 … 18.6 .001 † …
 Distant failure … 17.2 … 66.4 … 9.8  , .001 † …
5-year overall mortality rates … 42.4 … 76.9 … 36.5 .001 † …
Pathologically Determined N0 Stage
Crude incidence rates
 Local-regional failure 11/68 16.2 3/7 42.9 8/61 13.1 .06 5
 Distant failure 11/68 16.2 5/7 71.4 6/61 9.8 .001 23
5-year actuarial failure rates
 Local-regional failure … 15.0 … 58.3 … 10.9 .004 …
 Distant failure … 15.9 … 82.9 … 8.8  , .001 …
5-year overall mortality rates … 38.4 … 85.7 … 32.9 .001 …
Pathologically Determined N1 Stage
Crude incidence rates
 Local-regional failure 11/22 50.0 4/6 66.7 7/16 43.8 .3 …
 Distant failure 4/22 18.2 2/6 33.3 2/16 12.5 .3 …
5-year actuarial failure rates
 Local-regional failure … 55.5 … 77.8 … 48.7 .6 …
 Distant failure … 22.9 … 44.4 … 14.4 .3 …
5-year overall mortality rates … 54.5 … 66.7 … 50.0 .3 …
* Data are numbers used to calculate percentages.
 †  P value of comparison between two curves during whole follow-up.
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negative rates may be reduced with 
more vigorous evaluation of the medi-
astinum ( 22,23 ). 
 Beyond the surgical issues, there are 
uncertainties in the pathologic assess-
ment of resected tissues. A pathologic 
study showed that 63% (38 of 60) of pa-
tients with NSCLC who were considered 
to be tumor free with hematoxylin-
eosin staining had at least one positive 
LN detected with further immunohisto-
logic analysis, and 10% of LNs deter-
mine to be tumor free with hematoxylin-
eosin in LN-positive patients were found 
to be positive ( 24 ). Studies have sug-
gested that LN micrometastases in pa-
tients with early-stage pathologic N0 
NSCLC after curative surgery may be 
prognostic for recurrence and survival 
( 25,26 ). 
 Therefore, it is reasonable to hypoth-
esize that the discrepancies between 
PET and histologic fi ndings refl ect, at 
least in part, false-negative histologic 
fi ndings due to insuffi cient evaluation 
of the mediastinum at surgery through 
sampling. PET, on the other hand, al-
lows comprehensive evaluation of the 
mediastinum in a noninvasive fashion. 
 Most diagnostic tests, and particu-
larly PET, have relatively high positive 
predictive values in the chest and me-
diastinum, with histologic examination 
as the reference standard. The positive 
predictive value of PET in the mediasti-
num in patients with NSCLC has been 
reported to be 87% by Fischer et al 
( 27 ), 79% by Toloza et al ( 28 ), 90% by 
Dwamena et al ( 29 ), and 94% by Silvestri 
et al ( 8 ) in reviews with large popula-
tions. Factors reported to be related to 
false-positive PET fi ndings are infection 
(eg, pneumonia), benign infl ammatory 
disease (eg, tuberculosis), rheumatoid 
arthritis, non–insulin-dependent diabe-
tes, and atypical adenomatous hyper-
plasia ( 30 ), most of which can be de-
tected with routine admission tests. 
 Pathologic evaluation is generally 
considered to be the reference standard 
for staging many cancers. As such, treat-
ment recommendations are widely based 
on the results of histologic examina-
tions. Our analysis challenges that pre-
sumption, at least for situations when 
the radiologic and pathologic fi ndings 
the mediastinum has been demonstrated 
to increase detection of N2 disease 
as well as survival by multiple authors. 
In the recently completed American 
College of Surgeons Oncology Group 
Z0030 trial of mediastinal dissection 
versus systematic sampling in patients 
with T1 or T2, N0 or nonhilar N1 lung 
cancer, 4% of patients were found to 
have occult N2 disease despite negative 
rigorous prerandomization mediasti-
noscopy and/or thoracotomy or VATS 
( 19,20 ). A 2001 survey by the Ameri-
can College of Surgeons demonstrated 
a low rate of mediastinal evaluation in 
the United States: 27% of patients re-
ceived preoperative mediastinoscopy, 
46.6% had mediastinal LN biopsy, and 
58% had mediastinal LNs sampled or 
removed during surgery ( 21 ). False-
thoracotomy or VATS, access to the 
ipsilateral mediastinum may be better 
than with mediastinoscopy in some set-
tings, yet the access to the contralateral 
mediastinum is limited. This might be 
more of a factor for left lower lobe le-
sions that appear to have a greater pro-
pensity to metastasize to the contralat-
eral level 2 and 4 compared with other 
lobes ( 16 ). The false-negative rate of 
VATS is reported to be approximately 
7% on the basis of limited mostly retro-
spective data ( 15 ). These false-negative 
fi ndings could be refl ecting the chal-
lenging assessment of the mediastinum 
and/or the diligence of LN evaluation 
(complete dissection, systemic sampling, 
or selective sampling [currently the most 
common]) ( 17,18 ). The debatable pro-
cedure of complete nodal dissection of 
 Figure 2 
  
 Figure 2: Comparison of actuarial  (a) local-regional failure,  (b) distant failure, and  (c) overall mortality after 
surgery for patients with positive PET N2 fi ndings versus those with negative fi ndings. 
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outcomes. This suggests that one should 
be cautious when using SUV alone. While 
SUV may be the best method of image 
quantifi cation and a strong tool in the 
research setting, it may not be able to 
replace evaluation of PET images by an 
experienced physician who can consider 
the clinical context. 
 Our study had several limitations. 
First, there are inherent inaccuracies 
to retrospective data collection mostly 
due to errors from cofounding factors 
to be mentioned below. PET fi ndings 
and clinical outcomes were determined 
from records review. However, several 
physicians with expertise in lung cancer 
were involved in the record review, and 
records of patients suspected of having 
a local-regional recurrence were also re-
viewed by a thoracic surgeon. Second, the 
modest sample size limits the power 
of statistical analyses. Third, there are 
several factors that may confound one’s 
ability to assess the independent prog-
nostic relevance of the mediastinal PET 
fi ndings. For example, tumor size, lym-
phovascular space invasion, and the 
number of sampled mediastinal nodal 
stations may infl uence the rates of local-
regional or distant failure. Indeed, 
several of such factors were prognos-
tic in our univariate and multivariate 
analyses, as well as in other reports 
( 32 ). Nevertheless, in our multivariate 
analysis, the mediastinal PET fi ndings 
remained signifi cant. Further, the data 
presented represents a reasonably large 
group of patients treated and followed 
in a real-life clinical environment. Ad-
ditional study involving a larger num-
ber of patients, ideally with prospective 
data collection, would be helpful to bet-
ter understand this issue. 
 In conclusion, our fi ndings suggest 
that, in patients with NSCLC, preop-
erative evaluation of the mediastinum 
with PET may complement the surgical 
and histologic fi ndings. Among patients 
with a negative pathologic assessment 
of the mediastinum, those with an 
abnormality in the mediastinum at PET 
have a higher rate of local-regional and 
distant failure than do those without. 
Thus, positive PET fi ndings in the face 
of negative histologic fi ndings may 
represent a false-negative pathologic 
not alter recommendations for chemo-
therapy. However, this is less often true 
for patients with N0 disease, for whom 
chemotherapy is generally not recom-
mended. In these patients, the higher 
rate of distant failure in those with 
positive preoperative mediastinal PET 
fi ndings might lead to the recommen-
dation to receive chemotherapy. Since 
postoperative radiation therapy is gen-
erally not recommended for patients 
with stage N0 or N1 disease, the higher 
rate of local-regional failure in patients 
with a positive preoperative PET fi nding 
in the mediastinum might lead to con-
sideration of postoperative radiation 
therapy. Thus, the potential effect of 
our study in altering therapy might be 
different between N0 and N1 groups. 
 The signifi cant results in our analy-
sis are based on visual (ie, qualitative) 
interpretation of PET images, taking 
into account both attenuation-corrected 
and non–attenuation-corrected PET 
image sets as well as the pretest likeli-
hood of disease in certain mediastinal 
nodal stations as described earlier. In 
contrast, SUV-based (ie, quantitative) 
evaluation did not signifi cantly predict 
are discordant in the mediastinum. The 
high rates of local-regional and distant 
failures in our patients who had posi-
tive PET fi ndings in the mediastinum, 
despite negative histologic fi ndings, are 
interesting and suggest that these pa-
tients might benefi t from adjuvant 
postoperative therapies, such as chemo- 
and/or radiation therapy. In light of the 
generally good positive predictive value 
for PET imaging in the mediastinum as 
well as the risks of false-negative fi nd-
ings with surgical assessment of the 
LNs, the results of our analysis are not 
really surprising. There is ample data 
demonstrating the prognostic value of 
PET in lung cancer ( 31 ) and in other tu-
mor sites, such as cervical cancer ( 24 ). 
 The broad fi ndings of our study are 
roughly similar in the pathologically de-
termined N0 and N1 subsets. For both, 
the rates of local-regional and distant 
failure are higher in the groups with 
positive mediastinal PET fi ndings ver-
sus those with negative fi ndings. Most 
patients with N1 disease will be rec-
ommended to receive chemotherapy. 
Therefore, positive preoperative PET 
fi ndings in the mediastinum will likely 
 Table 3 
 Univariate and Multivariate Analyses 





Variable  P Value
Hazard 
Ratio  P Value
Hazard 
Ratio  P Value
Hazard 
Ratio  P Value
Hazard 
Ratio
Positive mediastinal PET 
 fi ndings 
.002 4.2  , .001 7.5 .093 1.9  , .001 6.9
Lymphovascular space 
 invasion
 , .001 6.8 .001 6.5  , .001 7.1 .01 4
Higher histologic grade .03 2.4 .3 … .13 … … …
Primary tumor size .09 … .02 1.2 .38 … .1 …
Male vs female sex .16 … .02 5.5 … … .14 …
Pleural involvement .13 … .02 3.6 … … .22 …
Increased no. of sampled 
 N2 stations
.13 … .84 … … … … …
Histologic fi ndings * .34 … .33 … … … … …
Left vs right .55 … .28 … … … … …
Type of surgery † .2 … .7 … … … … …
Postoperative chemotherapy .63 … .44 … … … … …
* Squamous vs nonsquamous carcinoma.
 † Lobectomy vs bilobectomy vs pneumonectomy.
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assessment, rather than a false-positive 
PET fi nding. 
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